Successful financing round for pharmaceutical company AMW

AMW GmbH (Arzneimittelwerk Warngau) has received follow-on financing to advance the development and commercialization process for its drug delivery systems. Together with BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM-Fonds and IBG Beteiligungsgesellschaft, the existing investors are putting in a total of up to seven million euros. The funds will be used for the marketing of the existing product portfolio and the development of a new technology for the controlled release of pharmaceuticals. AMW GmbH produces active ingredient implants as well as transdermal systems in the fast-growing fields of oncology, pain therapy and neurology.

read more